Future microbiologyOct 14, 2025

Using modified bacteria carrying HPV-16 cancer markers to improve immune cell vaccine effectiveness for cervical cancer

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Mar 18, 2026

Abstract

Recombinant Lactococcus lactis carrying the HPV-16 E6E7 fusion protein demonstrated significant immunological activity.

The vaccine induced antigen-specific T helper type 1 and cytotoxic T lymphocyte responses.
Activation of was promoted, enhancing their ability to stimulate T lymphocyte proliferation.
The DC-based vaccine exhibited potential anti-tumor effects by inhibiting tumor growth in a C57BL6 mouse model.
Lactococcus lactis is regarded as safe and may serve as an effective vehicle for tumor antigen delivery.

Simplified

AIMS: Anti-tumor vaccines that target the early proteins E6 and E7 of human papillomavirus (HPV) type 16 represent a potential immunotherapy for cervical cancer, although underlying mechanisms remain unclear. Lactococcus lactis () is generally regarded as safe (GRAS) which has potential as vehicle. Study investigated the immunoregulatory effect ofon (DCs) activation. Besides, antigen delivery and anti-tumor effects of DC-based vaccine prepared with recombinantvaccine (-De) carrying prokaryotic-eukaryotic HPV-16 E6E7 fusion antigen were explored. L.L L.L L.L L.L

METHODS: Study performed flow cytometry and MTT to analyze the adjuvant efficacy in promoting DC activation and proliferative capacity of T lymphocytes. The anti-tumor effect of DC vaccine prepared with-De was assessed in C57BL6 tumor model. L.L

RESULTS: Recombinantcarrying the expression frame for HPV-16 E6E7 fusion protein in prokaryotic-eukaryotic expression systems exhibited antigen-promoting and cross-presenting adjuvant activity successfully. the developed DC--De vaccine induced antigen-specific Th-1 and cytotoxic T lymphocyte responses, which inhibited TC-1 tumor growth. L.L L.L

CONCLUSIONS: This study demonstrated that recombinantwhich carries a dual-expression antigen frame, is a promising vector for tumor antigen delivery. L.L

Key numbers

P < 0.05

Increase in T lymphocyte proliferation

Comparison of T lymphocyte proliferation between treatment and control groups.

p < 0.05

Tumor growth inhibition

Comparison of tumor growth in vaccinated vs. control groups.

Full Text

We can’t show the full text here under this license.

View Full Text ↗

Using modified bacteria carrying HPV-16 cancer markers to improve immune cell vaccine effectiveness for cervical cancer

Abstract

Key numbers

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief